• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma

Video

Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of PADRES (prior axitinib as a determinant of outcome of renal surgery NCT03438708) clinical trial,” which he presented at the 2022 AUA Annual Meeting (LBA01-08).

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.